Breakthrough Solutions for Autoimmune
Skin Diseases

A New Approach to Treating Autoimmune Skin Diseases

Regranion, LLC is a clinical-stage pharmaceutical company delivering breakthrough solutions for autoimmune skin diseases by targeting a conserved pathway that contributes to hyperinflammation.

RGRN-305, our lead product, is an orally delivered potent small molecule inhibitor of heat shock protein 90 (HSP90) that has demonstrated activity as a broad-spectrum anti-inflammatory molecule and clinical safety and efficacy in patients with autoimmune skin disease.

  • Unique mechanism of action confers clear market differentiation

    RGRN-305 is a broad-spectrum anti-inflammatory molecule that targets multiple inflammatory mediators of dermal diseases, rather than an individual cytokine or chemokine

  • Commercial opportunity in numerous indications with high unmet clinical need

    RGRN-305 downregulates key inflammatory mediators of psoriasis, atopic dermatitis, bullous pemphigoid, and hidradenitis suppurativa

  • Clinically proven safety and efficacy profile

    No ocular, CNS, or cardiac toxicity and no consistent changes in hematology or biochemistry parameters in clinical trials; efficacy in resolving plaque psoriasis symptoms in a Phase 1b clinical trial

RGRN-305 has proven results in
moderate to severe plaque psoriasis

Before Treatment

Before Treatment

After Treatment

After Treatment

Technology Overview and Therapeutic Approach

RGRN-305 is an orally delivered small molecule heat shock protein 90 (HSP90) inhibitor. Active participation of HSP90 in immune processes has been recognized in autoimmune skin diseases, and inhibition of HSP90 has emerged as a promising approach to preventing widespread pathological inflammation.

Product Pipeline

RGRN-305 is in development for multiple indications of autoimmune skin diseases including psoriasis, atopic dermatitis, hidradenitis suppurativa, and bullous pemphigoid.